Novel psychoactive substances
Sample Mining and Data Mining: Combined Real-Time and Retrospective Approaches for the Identification of Emerging Novel Psychoactive Substances
The Detection of Novel Stimulants in Oral Fluid From Users Reporting Ecstasy, Molly and MDMA Ingestion
Analytical Studies on the 2-naphthoyl substituted-l-n-pentylindoles Regioisomeric Synthetic Cannabinoids
In Vitro Metabolism of Desomorphine
A Comparison of Single Quadrupole Mass Detection and Diode Array Ultraviolet Detection Interfaced to Uultra-high Performance Supercritical Chromatography for the Quantitative Analysis of Synthetic Cathinones
The Role of Diode Array Ultraviolet Detection for the Identification of Synthetic Cathinones
Decreasing the Uncertainty of Peak Assignments for the Analysis of Synthetic Cathinones Using Multi-dimensional Ultra-high Performance Liquid Chromatography
N-Ethyl Pentylone (Ephylone) Intoxications: Quantitative Confirmation and Metabolite Identification in Authentic Human Biological Specimens
Assessing the Activity of Synthetic Opioid AH-7921 and U-47700 Analogs in Cloned Human Mu-Opioid Receptor Expressing Fibrosarcoma HT-1080 Cells
Stability of Synthetic Cathinones in Urine
Stability of Synthetic Cathinones in Blood
Differentiation of Methylated Indole Ring Regioisomers of JWH-007: GC-MS and GC-IR Studies
Formation and Identification of Novel Derivatives of Primary Amine and Zwitterionic Drugs
Characterization of 2C-phenethylamines Using High-Resolution Mass Spectrometry and Kendrick Mass Defect Filters
Identification and Quantification of Synthetic Cathinones in Blood and Urine Using Liquid Chromatography-Quadrupole/Time of Flight (LC-Q/TOF) Mass Spectrometry
A Data-Informed Response to Emerging Drugs
The emerging drug crisis in the U.S. touches both criminal justice and public health, and experts from both fields came together at NIJ’s 2023 National Research Conference to discuss strategies and tools to fight this problem. Dr. Frances Scott, NIJ scientist and program manager, continues the conference discussion with two fellow panelists: Ciena Bayard, the Method Development and Validation Program Manager for D.C. Office of the Chief Medical Examiner, and Haley Greene, the Deputy Epidemiologist for the Central Region for the Virginia Department of Health. Read the transcript.